טוען...
Thrombin Mutant W215A/E217A Treatment Improves Neurological Outcome and Reduces Cerebral Infarct Size in a Mouse Model of Ischemic Stroke
BACKGROUND AND PURPOSE: Treatment of ischemic stroke by activation of endogenous plasminogen using tissue plasminogen activator (tPA) is limited by bleeding side effects. In mice, treatment of experimental ischemic stroke with activated protein C (APC) improves outcomes; however, APC also has bleedi...
שמור ב:
| Main Authors: | , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
2011
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3115697/ https://ncbi.nlm.nih.gov/pubmed/21512172 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/STROKEAHA.110.603811 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|